Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy
NCT04629885Phase 2Completed
- Sponsor
- Peptonic Medical
- Start
- May 2016
- Primary completion
- May 2017
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vagitocin in Vulvovaginal atrophy (VVA) (4 arms), sponsored by Peptonic Medical. Primary endpoint: Change in severity of the most bothersome VVA symptom at 12 weeks. Started May 2016; status: completed.
02
Drugs
vagitocin
03
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT04629885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629885.